Incyte
NEWS
Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades.
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
Astra and Incyte are pushing forward on the development of immunotherapy combination treatments.
Incyte picked up MGA012 and the exclusive rights to develop the drug worldwide.
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
Incyte has levelled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former CSO who had access to Incyte’s scientific research.
JOBS
IN THE PRESS